-
Many pharmaceutical companies listed on National Chengda Biotech Innovation Board release Q3 financial reports
Time of Update: 2021-11-15
Sichuan Province issued the implementation rules for the management of traditional Chinese medicine granules; Takeda announced the acquisition of the γδT cell therapy platform; Yibai Pharmaceutical plans to acquire 70% of the shares of Deyang Cancer Hospital for 336 million yuan.
-
Advances in drugs for attention deficit hyperactivity disorder (ADHD)
Time of Update: 2021-11-15
A 40-week randomized double-blind placebo-controlled multi-center clinical efficacy and safety study phase III trial of Novartis (NCT01259492) pointed out that the treatment failure rate (21.
-
Pfizer China "New Head" Peng Zhenke: Decoding New Pfizer Helps Sustainable Development of Medical and Health Industry
Time of Update: 2021-11-14
Facing new changes, mobilizing resources for a win-win cooperation In recent years, with the introduction of a series of favorable policies such as import "zero tariff" and the reform of the drug review and approval system, and the joint promotion of national policies supported by China's innovative drugs, many outstanding local innovative drug R&D companies have emerged .
-
Kunyao Group and Wangshi Wisdom signed a small molecule drug cooperation development agreement again
Time of Update: 2021-11-14
Joining forces again this time, Wangshi Wisdom CEO Zhou Jielong said that Kunyao Group has a distinctive R&D layout, and continues to invest in the field of innovative drugs to strengthen its existing advantages .
-
What is the difference between the three antisense therapies of Ionis in the treatment of neurodegenerative diseases?
Time of Update: 2021-11-14
Anastasia Khvorova, who leads the Therapeutic RNA Laboratory at UMass Medical School, attributed the failure of drug development to the treatment of Huntington’s disease and gradual freezing in part to the difference between the two antisense molecules: RNA blockers And RNA degrading agent .
-
The market value has shrunk by 90%, and Golden Voice announces its delisting
Time of Update: 2021-11-14
On November 1, the stock price decline caused by the sudden announcement of the delisting of Golden Voice continued .
On November 1, the stock price decline caused by the sudden announcement of the delisting of Golden Voice continued .
-
Three Progresses in the Diagnosis of Alzheimer's Disease
Time of Update: 2021-11-14
. Three major advances in the recent exploration of the diagnosis of Alzheimer's disease include: blood biomarker analysis, polygenic risk score, and non-invasive technology .
-
Songhua New Tea)Wuhan Jiangan Silk Foot Health_Tencent News
Time of Update: 2021-11-13
DK's crystal collapsed, and EDG finally defeated its opponent 3:2 and won the S11 global finals .
DK players even said in an interview before the game that they would take away their opponents 3:0 .
-
Comprehensive analysis, one article to understand the liposome encapsulation rate
Time of Update: 2021-11-12
The dialysis method is also a common method to determine the encapsulation efficiency, which is suitable for water-soluble drugs, but the dialysis time is generally longer than 36 hours, which has high requirements for liposome stability; in addition, the addition of a large amount of dialysis medium will also dilute the liposomes System, may also cause liposome leakage .
-
SF UAV and Luohu People's Hospital jointly carry out normalized medical delivery
Time of Update: 2021-11-12
In August 2021, Luohu Hospital Group and SF Express reached a cooperation to open up a rapid air transportation channel for test samples, and jointly land a smart medical integrated solution based on drone logistics, which can transport a variety of samples such as blood tests, nucleic acids, and urine tests, and Various materials such as medicine and tools .
-
Kallmann Syndrome (Kallmann Syndrome) of Rare Disease Series
Time of Update: 2021-11-04
Treatment At present, patients with Kalman syndrome need long-term medication replacement therapy to maintain secondary sexual characteristics and hormone homeostasis in the body, and improve the quality of life .
-
GPC3 research and development is expected to break through the restricted area of CAR-T treatment of solid tumors
Time of Update: 2021-11-04
In 2017, Cancer Chemother Pharmacol published the results of a phase II trial of GC33 combined with sorafenib in the treatment of advanced hepatocellular carcinoma.
-
Nearly 2 billion people with latent infections, the tuberculosis war has never ceased-an overview of multi-drug-resistant pulmonary tuberculosis drugs
Time of Update: 2021-11-04
At present, the highest research and development stage of the drug is clinical phase II, which is used to prevent tuberculosis, new coronavirus pneumonia and multi-drug resistant tuberculosis .
-
P53 upstream & synthetic lethal: the target "ATM" track has great potential!
Time of Update: 2021-11-03
? XRD-0394 development company is X Rad Therapeutics, which is administered orally and is a dual ATM/DNA-PK inhibitor for the treatment of metastatic, locally advanced or recurrent solid tumors .
-
The past, present and future of therapeutic antibody engineering
Time of Update: 2021-11-03
One disadvantage of this technology is that due to antigen processing and imaging of mouse genetic factors regulated by B cells, the monoclonal antibodies obtained may not be as specific as the antibodies naturally produced in humans.
-
"Brain cancer" potential target LAT1 has clear drug design ideas
Time of Update: 2021-10-22
03 The substrate of the drug LAT1 transported by LAT1 needs to contain both a positively charged amino group and a negatively charged carboxyl group, as well as a hydrophobic or aromatic structure next to the central hydrogen bond acceptor.
-
Maintenance phase treatment of ovarian cancer, targeted or immune?
Time of Update: 2021-10-22
In 2018, based on the results of the clinical trial GOG-0218 (NCT00262847), the FDA approved bevacizumab combined with carboplatin and paclitaxel for use in stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneum after surgical resection Cancer treatment .
-
In-depth analysis of Hengrui's innovative drug design cases, exploring the gold-digging road of "Yao Mao"
Time of Update: 2021-10-21
In another ATR inhibitor patent of Hengrui (CN 113135942 A), the best possible compound 3 is obtained from AZD-6738 backbone transition, isosteric, and ring closure.
-
12 far-reaching medical discoveries
Time of Update: 2021-10-21
Fleming, Flory and Chann won the Nobel Prize in Physiology or Medicine in 1945 for "the discovery of penicillin and its clinical effects .
. In 1933, two scientists accidentally discovered warfarin while studying the cause of blood loss in cattle.
-
Trax at the scene: the way of store execution management for medical and health companies
Time of Update: 2021-10-20
A well-known leading pharmaceutical and healthcare company used Trax crowdsourcing solutions to achieve a 10% increase in store inventory rate, a 15% reduction in price default rate, a 38% increase in first launch implementation rate, and a 15% store address library update .
